RT Journal Article
SR Electronic
T1 Rett syndrome severity estimation with the BioStamp nPoint using interactions between heart rate variability and body movement
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.21.22272708
DO 10.1101/2022.03.21.22272708
A1 Suresha, Pradyumna Byappanahalli
A1 O’Leary, Heather
A1 Tarquinio, Daniel C.
A1 Von Hehn, Jana
A1 Clifford, Gari D.
YR 2022
UL http://medrxiv.org/content/early/2022/03/22/2022.03.21.22272708.abstract
AB Rett syndrome, a rare genetic neurodevelopmental disorder in humans, does not have an effective cure. However, multiple therapies and medications exist to treat symptoms and improve patients’ quality of life. As research continues to discover and evaluate new medications for Rett syndrome patients, there remains a lack of objective physiological and motor activity-based (physio-motor) biomarkers that enable the measurement of the effect of these medications on the change in patients’ Rett syndrome severity. In our work, using a commercially available wearable chest patch, we recorded simultaneous electrocardiogram and three-axis acceleration from 20 patients suffering from Rett syndrome along with the corresponding Clinical Global Impression - Severity score, which measures the overall disease severity on a 7-point Likert scale. We derived physio-motor features from these recordings that captured heart rate variability, activity metrics, and the interactions between heart rate and activity. Further, we developed machine learning (ML) models to classify high-severity Rett patients from low-severity Rett patients using the derived physio-motor features. For the best-trained model, we obtained a pooled area under the receiver operating curve equal to 0.92 via a leave-one-out-patient cross-validation approach. Finally, we computed the feature popularity scores for all the trained ML models and identified physio-motor biomarkers for Rett syndrome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02696044Funding StatementGDC is partially supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. URL: https://ncats.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Emory Institutional Review Board (IRB00088492: Outcome Measures and Biomarkers Development for Rett Syndrome and Multisite development of standardized assessments for use in clinical trials). A written informed consent was received prior to the participation from the parents of the patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData will be posted on PhysioNet (https://physionet.org/) in due course, after de-identification has been verified and permissions for public posting have been secured. Early access to data can be achieved by contacting the authors. The data contains Patient Health Information and hence cannot be publicly shared before de-identification.